Clindamycin Veterinary Grade API is supplied as clindamycin hydrochloride, a lincosamide antibacterial active pharmaceutical ingredient intended for incorporation into tablets, injections, capsules, powders, granules, premixes, and solutions for companion and food-producing animal species. The product is designated by article code CLN-VET-HCl-500; the article code denotes the hydrochloride salt, veterinary release testing, and a nominal bulk package of 25 kg in a food-grade fibre drum with double polyethylene liners. The API is a white or almost white crystalline powder with the molecular formula C₁₈H₃₃ClN₂O₅S·HCl and a relative molecular mass of 461.44 g/mol. The CAS registry number is 21462-39-5. The material is supplied to meet the current USP monograph for clindamycin hydrochloride, the current Ph. Eur. monograph, and relevant regional veterinary pharmacopoeial requirements. The product is not a sterile API; injectable dosage forms must be sterilised by terminal moist-heat sterilisation or aseptic filtration after dissolution and final pH adjustment, unless otherwise justified by thermal degradation studies.

Why Is the Hydrochloride Salt Selected Over Clindamycin Palmitate Hydrochloride and Clindamycin Phosphate for Veterinary Formulations?

Clindamycin hydrochloride contains the active base in water-soluble salt form and does not require enzymatic or pH-dependent hydrolysis to release the active moiety. This property makes it suitable for oral powders, granules, premixes, and injectable solutions where rapid dissolution and uniform distribution in water or feed are required. Clindamycin phosphate is a semisynthetic ester prodrug more commonly used in human intravenous and topical products because its phosphate ester improves aqueous compatibility and reduces injection-site discomfort after neutralisation. The phosphate moiety must be cleaved to yield clindamycin base, and assay expression must use a molecular-weight conversion factor. Published data for direct comparative bioavailability across all veterinary target species is limited; therefore, when a formulation contains clindamycin phosphate, equivalence should be demonstrated in the target species rather than assumed from hydrochloride salt data. Clindamycin palmitate hydrochloride is an oral ester intended for taste masking in paediatric liquid formulations. Its lower water solubility and the need for hydrolysis in the gastrointestinal tract make it less suitable for feed premixes and dry powder formulations. The hydrochloride salt is preferred because it provides a high clindamycin base content per unit mass and a pH range compatible with acidified oral and injectable systems.

Veterinary grade clindamycin hydrochloride differs from human grade primarily in regulatory and supply-chain controls. The veterinary grade is accompanied by target animal safety data, TSE/BSE declarations, and statements addressing potential cross-contamination with beta-lactam compounds in medicated feed applications. Chemically, the molecule is identical, but human-grade material is not automatically accepted for veterinary use because residue depletion, withdrawal period, and species-specific formulation compatibility must be established for the intended animal species.

Release testing for the veterinary-grade material is organised around three intended use classes: solid oral dosage forms, injectable solution compounding, and medicated feed premix or oral solution. The assay is expressed as clindamycin base on an anhydrous basis, with an acceptance range of 800–1050 µg/mg. Water content determined by Karl Fischer titration is controlled to 3.0–6.0%. The pH of a 10% aqueous dispersion is controlled between 3.0 and 5.5; excursions above 6.5 reduce solubility and may produce free-base precipitation in concentrated stock solutions. Specific optical rotation on the anhydrous basis is expected in the range +135° to +150° when tested at the sodium D-line. Related substances are controlled by gradient high-performance liquid chromatography; regional pharmacopoeial limits for lincomycin hydrochloride and total impurities are applied, with the stricter criterion selected when monographs differ. Elemental impurities are tested by inductively coupled plasma mass spectrometry and reported against the oral, parenteral, and feed-medication limits of ICH Q3D. Residual solvents are tested by headspace gas chromatography and controlled according to ICH Q3C. Polymorphic identity is controlled by X-ray powder diffraction because changes in crystalline form can alter dissolution and bulk density even when chemical assay remains unchanged.

When the Same API Lot Is Designated for Oral Premix and Injectable Compounding

If a single lot is released for both oral premix and injectable compounding, the tighter parenteral controls must be applied to the entire lot: bacterial endotoxins, bioburden, particulate behaviour, and water content. Endotoxin limit for an injectable product is not a fixed API limit; it is calculated from the maximum endotoxin dose permitted per kilogram of body weight and the maximum dose volume under USP <85> and Ph. Eur. 2.6.14. The API supplier should provide a documented endotoxin value with method validation data. For a 150 mg/mL clindamycin hydrochloride injection, an API control at or below 0.50 EU/mg may be suitable, but this must be confirmed using the final formulation and target species weight band. Bioburden should be controlled below 100 CFU/g for non-sterile APIs entering aseptic filtration. For terminal moist-heat sterilisation cycles at 121 °C for 15 min, the requirement may be less stringent, but the thermal degradation profile of clindamycin hydrochloride under the exact solution pH should be generated because the drug is more stable at acid pH and may degrade with pH shift during heating. The finished injectable is not sterile solely because the API has low bioburden; sterility assurance is provided by the downstream process and verified by USP <71>. For oral premix and powder, the same tighter testing is acceptable but not required; medicated feed applications are governed separately by blend homogeneity, carryover control, and species-specific withdrawal periods.

Particle-Size Reduction and Moisture Uptake Controls for Solid Dosage Processing

Clindamycin hydrochloride crystals are typically needle-like, and the powder exhibits cohesive flow and high electrostatic adhesion at relative humidity below 30%. Direct compression of clindamycin hydrochloride with standard microcrystalline cellulose and magnesium stearate is possible only at low dose strengths; at API loadings above 20%, flow function coefficient values can fall below 4, indicating cohesive flow. Dry granulation by roller compaction or wet granulation is therefore used for tablet and capsule strengths of 25 mg, 75 mg, and 150 mg clindamycin base equivalent. Granulation with water at 6–10% w/w as binder in a high-shear mixer produces granules with bulk density 0.45–0.60 g/mL and D50 120–250 µm. After drying at inlet air temperature 50–60 °C to loss-on-drying below 2.0%, the granules are milled through a 1.0 mm screen. Tablets compressed at 15–25 kN using 8–10 mm round concave tooling typically achieve hardness 6–10 kp and disintegration below 15 min in 0.1 M hydrochloric acid. These values are starting points; each formulation must be optimised because clindamycin hydrochloride is sensitive to moisture and can produce sticky granulations when roller compactor gap pressure exceeds 30 kN.

Medicated feed premix preparation requires the API to be diluted with a carrier such as lactose monohydrate, corn cob, or calcium carbonate. The geometric dilution sequence should maintain active concentration at 2–10% w/w for intermediate premix and below 1% w/w for final feed. Blend uniformity is tested by thief sampling at 10 locations with assay acceptance at 90.0–110.0% of label claim. Published data for every carrier system used in swine or poultry premix is limited; therefore, carrier selection should be confirmed by blend uniformity and stability retention studies in the intended feed matrix. Clindamycin hydrochloride is incompatible with strongly alkaline carriers and bulk feed additives that raise local pH above 6.5, because free-base precipitation can reduce availability. Avoid combination with bentonite or other high-surface-area clay binders at levels that may adsorb the drug and slow release unless in vitro release testing demonstrates acceptable dissolution under USP <711> conditions adapted for veterinary premix.

For aqueous oral solutions and reconstituted granulates, the target solution pH should be maintained between 3.0 and 5.5 using citrate or phosphate buffer systems. Clindamycin hydrochloride is freely soluble in water, but concentrated solutions above 200 mg/mL may require warming and pH adjustment; cooling without stirring can cause crystallisation. Oral solutions should be protected from light and stored at controlled room temperature 20–25 °C; reconstituted solutions without demonstrated preservative efficacy should not be stored above 25 °C for more than 24 h. For injectable compounding, final filtration through a 0.22 µm membrane is required to reduce particulate matter and bioburden before aseptic filling, unless the formulation is terminally sterilised. Avoid combination with amine-based buffering additives that raise solution pH above 6.5, because clindamycin free base has limited solubility and may precipitate. The operational boundary for moisture exposure during solid dosage processing is relative humidity 60%; above this level, pre-drying of the API is required before blending because water uptake alters flow and can accelerate hydrolysis-related impurities during storage.